Market Shares of Overseas Pharma Enterprises Approach 70% in China’s Coagulation Factor Ⅷ Market

Related news: Novo Nordisk's Recombinant Coagulation Factor Ⅷ Applied for Marketing Ahead of Chiatai Tianqing!

Coagulation factor Ⅷ marketed in China includes the first generation, second generation, and third generation, wherein, Chinese pharmaceutical enterprises mainly market the first generation, and overseas pharmaceutical enterprises market the second and third generations. Roche's Emicizumab Injection has been marketed in China since the end of last year, which attracts much attention. As a recombinant humanized bispecific monoclonal antibody, emicizumab was approved by the U.S. FDA for marketing at the end of 2017; the drug has a longer action time compared to other hemophilia drugs and requires only one subcutaneous injection every week, being the only long-acting recombinant coagulation factor Ⅷ marketed in China at present.

 (Sorted out according to public data)

Market shares of overseas pharmaceutical enterprises and medical supplies suppliers have approached 70% in China's coagulation factor Ⅷ market at present.

The theoretical market size of coagulation factor Ⅷ exceeds RMB10 billion in China

According to the data of PDB, sales of coagulation factor Ⅷ in sample hospitals of China increased from RMB130 million in 2012 to RMB466 billion in 2017, with the compound annual growth rate of 29.15%. Amplified according to 5-6 times of the sales in sample hospitals in 2017, the current market size of coagulation factor Ⅷ is about RMB2.33-2.796 billion (averagely RMB2.563 billion) in China. According to a securities analyzer, the theoretical space of coagulation factor Ⅷ exceeds RMB16.8 billion as calculated according to 141,300 potential hemophilia A patients.

About  the Author:    

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content,

please email: Julia.Zhang@ubmsinoexpo.com